Treatment of Stage III or Stage IVA Nasopharyngeal Carcinoma

Stage III and stage IVA nasopharyngeal carcinoma represent locally advanced disease. A systematic, evidence-based treatment approach is required, and systemic treatment intensification is a key consideration at these stages.

Clinical scenario: Patients diagnosed with stage III or stage IVA nasopharyngeal carcinoma (ICD-10 C11 / ICD-11 2B6B) being evaluated for first-line definitive treatment.

Treatment approach

Concurrent chemoradiotherapy (CRT) — combining radiation therapy with a platinum-based agent — is the established treatment framework for this stage. Strategies for systemic treatment intensification are an integral part of the clinical decision.

Full agent selection, sequencing options, and intensification strategies are detailed in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2020.12.007

Stage III and IVA disease are treated by CRT [I, A].
The standard agent used is cisplatin [I, A].
Intensification of the systemic treatment is therefore needed for stage III-IVA non-keratinising NPC.

View source ↗